Johnson D E, Babaian R J, Swanson D A, von Eschenbach A C, Wishnow K I, Tenney D
Department of Urology, University of Texas, M. D. Anderson Hospital and Tumor Institute, Houston.
Urology. 1988 May;31(5):371-4. doi: 10.1016/0090-4295(88)90726-1.
Sixty-two men who presented with previously untreated metastatic carcinoma of the prostate (D0: 10 patients; D1: 29 patients; D2: 23 patients) received oral megestrol acetate (80 mg twice daily) and minidose estrogen (diethylstibestrol 0.1 mg or ethinyl estradiol 0.05 mg once daily) as a means of achieving total androgen ablation (testicular and adrenal). A high incidence of feminizing side effects (70-74%), a higher than expected rate of cardiovascular complications (18%), an unexpected need for cortisone replacement (13%), and failure of patients with Stage D2 disease to obtain results better than those of standard therapy during the first year of observation suggest this regimen offers no advantage over other more conventional therapy.
62例初治的前列腺转移性癌患者（D0期：10例；D1期：29例；D2期：23例）接受了醋酸甲地孕酮口服（每日2次，每次80mg）和小剂量雌激素（己烯雌酚0.1mg或炔雌醇0.05mg，每日1次）治疗，以实现完全雄激素阻断（睾丸和肾上腺）。女性化副作用发生率高（70 - 74%），心血管并发症发生率高于预期（18%），意外需要皮质醇替代治疗（13%），且在观察的第一年中，D2期疾病患者未能取得比标准治疗更好的结果，提示该治疗方案并不比其他更传统的治疗方法更具优势。
